143 related articles for article (PubMed ID: 37042459)
21. Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma.
Lee B; Bae YJ; Jeong WJ; Kim H; Choi BS; Kim JH
Sci Rep; 2021 Oct; 11(1):19717. PubMed ID: 34611230
[TBL] [Abstract][Full Text] [Related]
22. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
23. Sarcopenia as a Prognostic Marker in Elderly Head and Neck Squamous Cell Carcinoma Patients Undergoing (Chemo-)Radiation.
Haehl E; Alvino L; Rühle A; Zou J; Fabian A; Grosu AL; Nicolay NH
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428629
[TBL] [Abstract][Full Text] [Related]
24. Sarcopenia and Systemic Inflammation Synergistically Impact Survival in Oral Cavity Cancer.
Lee J; Liu SH; Dai KY; Huang YM; Li CJ; Chen JC; Leu YS; Liu CJ; Chen YJ
Laryngoscope; 2021 May; 131(5):E1530-E1538. PubMed ID: 33135827
[TBL] [Abstract][Full Text] [Related]
25. Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients.
Karavolia E; van Rijn-Dekker MI; Van den Bosch L; van den Hoek JGM; Oldehinkel E; Meijer TWH; Halmos GB; Witjes MJH; Oosting SF; van der Hoorn A; Langendijk JA; Steenbakkers RJHM
Radiother Oncol; 2022 May; 170():122-128. PubMed ID: 35304862
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Oral Oncol; 2019 Aug; 95():95-99. PubMed ID: 31345401
[TBL] [Abstract][Full Text] [Related]
28. Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma.
Roberti E; Merlano M; Ravanelli M; Alberti A; Esposito A; Gili R; Spinazzé S; Baré C; Jocollé G; Benasso M; Bertolotti F; Vecchio S; Bacigalupo A; Licitra L; Denaro N; Damico M; Lorini L; Gurizzan C; Alfieri S; Bossi P
Oral Oncol; 2023 Oct; 145():106540. PubMed ID: 37567147
[TBL] [Abstract][Full Text] [Related]
29. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma.
Guven DC; Erul E; Yilmaz F; Yasar S; Yildirim HC; Ercan F; Kaygusuz Y; Cayiroz K; Ucdal MT; Yesil F; Yazici G; Cengiz M; Gullu I; Aksoy S
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2471-2478. PubMed ID: 36565325
[TBL] [Abstract][Full Text] [Related]
30. High neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with squamous cell carcinoma of the head and neck treated with definitive chemoradiotherapy.
Chandrasekara S; Davis S; Thomson P; Haydon A
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e442-e447. PubMed ID: 29345108
[TBL] [Abstract][Full Text] [Related]
31. Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma.
Willemsen ACH; Hoeben A; Lalisang RI; Van Helvoort A; Wesseling FWR; Hoebers F; Baijens LWJ; Schols AMWJ
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):145-159. PubMed ID: 31536685
[TBL] [Abstract][Full Text] [Related]
32. The impact of skeletal muscle depletion on older adult patients with head and neck cancer undergoing primary surgery.
Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
J Geriatr Oncol; 2021 Jan; 12(1):128-133. PubMed ID: 32565144
[TBL] [Abstract][Full Text] [Related]
33. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
Chang PH; Yeh KY; Wang CH; Chen EY; Yang SW; Huang JS; Chou WC; Hsieh JC
Head Neck; 2017 Oct; 39(10):1990-1996. PubMed ID: 28688124
[TBL] [Abstract][Full Text] [Related]
34. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
[TBL] [Abstract][Full Text] [Related]
35. Development and Validation of an Automated Image-Based Deep Learning Platform for Sarcopenia Assessment in Head and Neck Cancer.
Ye Z; Saraf A; Ravipati Y; Hoebers F; Catalano PJ; Zha Y; Zapaishchykova A; Likitlersuang J; Guthier C; Tishler RB; Schoenfeld JD; Margalit DN; Haddad RI; Mak RH; Naser M; Wahid KA; Sahlsten J; Jaskari J; Kaski K; Mäkitie AA; Fuller CD; Aerts HJWL; Kann BH
JAMA Netw Open; 2023 Aug; 6(8):e2328280. PubMed ID: 37561460
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
[TBL] [Abstract][Full Text] [Related]
37. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
39. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
40. Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy.
Mollnar S; Pondorfer P; Kasparek AK; Reinisch S; Moik F; Stotz M; Halm M; Szkandera J; Terbuch A; Eisner F; Gerger A; Kapp KS; Partl R; Vasicek S; Weiland T; Pichler M; Stöger H; Thurnher D; Posch F
Clin Transl Oncol; 2021 Mar; 23(3):543-553. PubMed ID: 32671728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
